Lupin Limited

BSE
LUPIN
paper.types.company
Rentabilité sur six mois: -8.52%
Rendement en dividendes: 0.2475%

2 000.35 ₹

0 ₹ 0%
1555.1 ₹
2396.3 ₹

paper.min_max_per_year

Calendrier des promotions Lupin Limited

Calendrier avancé Graphique simple
Financial Markets by TradingView

À propos de l'entreprise Lupin Limited

Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India and internationally. It engages in the drug discovery, development, production, marketing, and sale of various branded and generic formulations, biosimilars, over-the-counter and specialty drugs, and active pharmaceutical ingredients (APIs).

plus de détails
The company offers formulations for use in the therapeutic areas of anti-tuberculosis, diabetes management, cardiovascular, chronic obstructive pulmonary diseases, asthma, gynecology and women's health, central nervous system, oncology, immunology, genomics, metabolic disorders, dermatology, urology, pediatrics, gastrointestinal, anti-infective, and nonsteroidal anti-inflammatory drug therapies, as well as engages in the bio clinical research activities. It operates through network consists of labs, LupiMitra collection centers, and pick-up points. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001. Lupin Limited was founded in 1968 and is headquartered in Mumbai, India.
Ajouter à la liste de comparaison
Ajouter à la liste de surveillance
Ajouter au portefeuille
Ajouter un avis de prix

Paramètres de base

ISIN
INE326A01037
Industry
Pharmaceuticals
Sector
Health Care
Валюта
inr
Валюта отчета
inr
Див.доход ао
0.2475
Дивиденд ао
8
Сайт
lien
Tous les paramètres

Grade

Sous-estimation
Nom Signification Grade
P/S 3.73 5
P/BV 5.1 3
P/E 38.27 4
Efficacité
Nom Signification Grade
ROA 8.15 3
ROE 14.31 4
ROIC 3.63 1
Dividendes
Nom Signification Grade
Rendement en dividendes 0.2475 0.63
DSI 0.9286 9.29
Croissance moyenne du dividende 7.18 10
Devoir
Nom Signification Grade
Debt/EBITDA 2.37 6
Debt/Ratio 0.1846 10
Debt/Equity 0.6695 9
Impulsion de croissance
Nom Signification Grade
Rentabilité Revenue, % 27.85 4
Rentabilité Ebitda, % -34.8 0
Rentabilité EPS, % -799.78 0
Plus de détails

paper.price.prices

Prix Common.min. Common.max. Changement paper.changes_in_industry paper.changes_in_index
common.calendar.number_days.1 2 000.35 ₹ 0 ₹ 0 ₹ 0 % 0 % 0 %
common.calendar.number_days.7d 1 993.7 ₹ 1 993.7 ₹ 2 027.55 ₹ 0.33 % 0 % 0 %
common.calendar.number_days.30d 1 979.05 ₹ 1 941.7 ₹ 2 068.35 ₹ 1.08 % 0 % 0 %
common.calendar.number_days.90d 1 921.3 ₹ 1 921.3 ₹ 2 121.3 ₹ 4.11 % 0 % 0 %
common.calendar.number_days.180d 2 186.65 ₹ 1 891.45 ₹ 2 396.3 ₹ -8.52 % 0 % 0 %
common.calendar.number_days.1y 2 172.2 ₹ 1 555.1 ₹ 2 396.3 ₹ -7.91 % 0 % 0 %
common.calendar.number_days.3y 662.25 ₹ 598 ₹ 2 396.3 ₹ 202.05 % 0 % 0 %
common.calendar.number_days.5y 844.6 ₹ 590.3 ₹ 2 396.3 ₹ 136.84 % 0 % 0 %
common.calendar.number_days.10y 0 ₹ 547 ₹ 2 396.3 ₹ 0 % 0 % 0 %
common.calendar.number_days.ytd 1 968.55 ₹ 1 891.45 ₹ 2 396.3 ₹ 1.62 % 0 % 0 %

Gestion d'entreprise

Superviseur Titre d'emploi Paiement Année de naissance
Ms. Vinita D. Gupta CEO & Executive Director 109.2M 1968 (57 années)
Mr. Nilesh Deshbandhu Gupta MD & Executive Director 49.6M 1974 (51 année)
Mr. Ramesh Swaminathan Global CFO, CRO, Head of Corporate Affairs & Executive Director 66.86M 1966 (59 années)
Mr. Christoph Funke Chief Technical Operations Officer
Mr. Sreeji Gopinathan Chief Information Officer
Dr. Shahin Fesharaki Global Chief Scientific Officer
Mr. Ravi Agrawal Sr. Vice President of Investor Relations and M&A
Dr. Sofia Mumtaz President of Legal and Compliance of Australia, Japan & Canada Business
Mr. Amit Kumar Gupta Company Secretary & Compliance Officer
Ms. Rajalakshmi Azariah Vice President & Global Head of Corporate Communications

Informations sur l'entreprise

Adresse: India, Mumbai, Kalpataru Inspire - Ouvrir dans google maps, Ouvrir les cartes yandex
Site web: https://www.lupin.com